All News

ROCKVILLE, Md--The Food and Drug Administration (FDA) has proposed rules that would give manufacturers greater flexibility in disseminating information about the safety, effectiveness, or benefits of "off label" uses of drugs, biologics, and medical devices. The new regulations will implement provisions of the FDA Modernization Act of 1997, enacted last year.

WASHINGTON--The mission of the FDA has historically been to respond to public needs and to protect public health, and the 1997 Modernization Act "will not divert the agency from this agenda," Michael Friedman, MD, the FDA’s lead deputy commissioner, said at a consumer forum sponsored by the FDA’s Office of Consumer Affairs.

Drs. McCarty and Kuhn have brought the readers up-to-date on a new technology--cryosurgery--that is available to treat malignant and benign tumors in the liver. The authors are cautiously optimistic regarding the ultimate success of this therapy. They present the current data, which were generated in patient groups that are the most difficult to treat--those with "unresectable" disease.

SAN DIEGO--Not wishing to be a self-contained island of clinical research in a region with a wealth of private cancer specialists, the Fred Hutchinson Cancer Research Center established a community outreach program to involve more oncologists in clinical trials, a program that now includes autologous transplants of peripheral blood stem cells (PBSCs), Leona Holmberg, MD, an associate in the clinical division at Hutch-inson, said at a conference sponsored by the University of California, San Diego.

Approximately 25 million persons each year in the United States are tested for antibody to human immunodeficiency virus (HIV). Publicly funded counseling and testing (CT) programs conduct approximately 2.5 million of these tests each year.

BETHESDA, Md--Forget about a better mousetrap, the National Cancer Institute wants to build better mice.

BUFFALO, NY--The cornerstone of a $241.1 million dollar major modernization project was unveiled at Roswell Park Cancer Institute. The new Diagnostic and Treatment Center and patient tower (Figure 1) feature state-of-the-art diagnostic imaging, radiotherapy, surgery, postanesthesia care, and intensive care units. The 5-year renovation of the 25-acre campus coincides with the Institute’s centennial anniversary.

WASHINGTON--National tobacco legislation may be decidedly down, but it is not definitely dead. Following the two votes in the Senate that defeated the comprehensive tobacco bill sponsored by Sen. John McCain(R-Ariz), Republicans and Democrats alike vowed to continue efforts to pass some form of legislation. But politicians throughout Congress are in such discord on details that many doubt any tobacco legislation will clear Congress and win the President’s signature in 1998.

NEW YORK--A new breast care center in New York City is offering same-day diagnosis, consultation with an on-site reconstructive surgeon, and an array of innovative services.

ORLANDO--Preoperative chemotherapy in breast cancer patients can leave a surgeon in the dark as to the specific amount of normal tissue to remove if the chemotherapy eliminates the tumor or renders it no longer palpable. A simple tattoo outlining the original tumor site can be a great aid in helping surgeons determine the type of surgery to be performed after the therapy.

MILAN, Italy--The cardiotoxicity seen in preliminary studies of bolus doxorubicin (Adriamycin) plus 3-hour paclitaxel (Taxol) (AT) proved to be reversible and mostly confined to patients who received more than 6 cycles of therapy, according to follow-up data presented at the ASCO meeting.

NEW ORLEANS--A monoclonal antibody isolated from a patient with stomach cancer appeared to cause specific cell death in tumors when infused into patients with stomach cancer prior to surgery, H. Peter Vollmers, PhD, said at the American Association for Cancer Research meeting. To look for an antibody that might target stomach cancer, the researchers removed B cells from the spleen of a patient with a diffuse adenocarcino-ma of the stomach and then isolated antibodies, said Dr. Vollmers, professor of experimental pathology, University of Würzburg, Germany.

Researchers at Ohio State University’s Comprehensive Cancer Center have determined the three-dimensional (3D) structure of the protein produced by the p16 tumor-suppressor gene. This protein normally prevents cells from dividing inappropriately.

LOS ANGELES--The Southwest Oncology Group (SWOG) is generally doing fine at enrolling women and African-Americans into clinical trials but is not doing so well at enrolling elderly patients, SWOG investigators reported at the ASCO annual meeting. SWOG biostatistician Joseph Unger found that the elderly were under-represented in almost every type of cancer clinical trial.

BALTIMORE--Adjuvant chemotherapy regimens for breast cancer are often reduced for patients over age 65 due to concerns about toxicity. These reductions may not be necessary in most cases. Elizabeth Claire Dees, MD, and her colleagues at the Johns Hopkins Oncology Center found that although older women had more neutropenia, this seldom resulted in clinical complications.

MADISON, Wisconsin--The Am-erican Association for Cancer Education (AACE) and the European Association for Cancer Education have joined with the WHO International Network for Cancer Education (INCE) to put together a traveling exhibit of cancer educational materials for display at cancer congresses around the world.

NEW ORLEANS--Analysis of stools of centuries-old mummies shows that some were infected with Helicobacter pylori, indicating that this bacterium, which colonizes the stomach and can cause ulcers and stomach cancer, has long plagued humans.

NEW ORLEANS--Curcumin and sulindac sulfone both can inhibit colon carcinogenesis in a rat model during the initiation and post-initiation stages. But a study from the American Association for Cancer Research meeting suggests that during the promotion and progression stages, only curcumin inhibits tumor development.

PASADENA, California--The health care system in the United States has been developed along the lines of medical specialization, which can lead to the fragmentation of patient care. Specialties are created by artificial divisions such as organ systems (cardiology, neurology); age (pediatrics, geriatrics); sex (urology, gynecology); disease (oncology); and function (surgery, obstetrics).

RESEARCH TRIANGLE PARK, NC--The National Toxicology Program has requested public input on 11 chemicals recommended for absorption, toxicity, or carcinogenicity studies. It seeks information from completed or ongoing studies, and information on planned studies, as well as current production data, human exposure information, use patterns, and environmental occurrences.

WASHINGTON--Two pediatric oncologists brought a plea to Capitol Hill that Congress pay greater attention to childhood cancers, both in terms of research funding and guaranteeing access to quality care.

Cowen and colleagues provide a very good review of thymomas. Although thymomas are the most common of the anterior mediastinal tumors, these tumors as a group are relatively uncommon. The authors focus their discussion on the pathology, staging, and management of thymomas.

Health care providers and financing organizations have become more aware of the resource constraints on the provision of medical services, thus increasing the importance of economic evaluations within the health care industry.[1,2] This has carried over to the evaluation of new, therapeutic strategies for cancer, which have traditionally been evaluated exclusively for safety and clinical efficacy.

Dr. Aboulafia provides an accurate overview of the relationship between immunodeficiency and malignant lymphoma, the lymphoproliferative disorders that occur following solid organ transplantation, and the epidemiology and pathogenetic mechanisms possibly involved in acquired immunodeficiency syndrome (AIDS)-related lymphomagenesis.

Acquired immunodeficiency syndrome (AIDS)-related lymphoma is a complex disease process with a range of features that are distinct from both non-Hodgkin’s lymphoma (NHL) outside of the context of immunodeficiency and the lymphoproliferative disease seen in immunodeficiency unrelated to human immunodeficiency virus-1 (HIV-1). Dr. Aboulafia lucidly summarizes the issues contributing to the unique aspects of this disease.

As indicated in this review by Patt and Ellison, the literature pertaining to the association between transitory acute pains and chronic cancer-related pain is limited and plagued by nomenclatural problems. Nonetheless, the clinical relevance of these so-called breakthrough pains is apparent to those who treat cancer patients.

It is striking how often medical advances occur as a result of the recognition of something that, in retrospect, is obvious. Pain has always been a feared consequence of disease, particularly cancer. Only in the past decade, however, has the widespread undertreatment of pain and its impact on the quality of life of patient and family gained the attention of mainstream medical research. Rapid, simultaneous advances in basic neurobiology and clinical investigation have dramatically improved the clinician’s ability to diagnose and treat pain.

The curative management of primary and metastatic liver tumors has traditionally relied on surgical resection. Unfortunately, fewer than 10% of newly diagnosed patients have tumors that are considered to be surgically

Among patients with congenital and acquired immunodeficiencies, non-Hodgkin’s lymphomas (NHLs) are the most common tumors of the immune system. In the setting of human immunodeficiency virus (HIV) infection, as

Thymomas are rare, slow-growing neoplasms that are considered to be malignant because of their potential invasiveness. The most widely used staging system is that of Masaoka and colleagues, which takes into account